Veteran Pharmaceutical Industry Executives Will Advise Portfolio Companies and Investment Team TORONTO, November 18, 2020 – Lumira Ventures, a leading North American healthcare venture capital firm, today announced the appointment of Theodore Witek, Jr., DrPH, MBA and Daniel Billen, PhD …
Trending at Lumira Ventures
“Oh, the Places You’ll Go”: A look back at the Canadian healthcare innovation industry and what lies ahead (Part 2)
The Takeaway is a periodic blog by Lumira Ventures that covers themes and trends within the fast-growing Canadian healthcare innovation ecosystem. Please note that the views and opinions expressed in this article are those of Lumira Ventures and do not …
enGene Receives Funding Through Cystic Fibrosis Foundation’s Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis
OSTON and MONTRÉAL, Oct. 29, 2020 /PRNewswire/ -enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today an award from the Cystic Fibrosis Foundation for the discovery of genetic medicines to treat patients …
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis August 24, 2020 06:59 AM Eastern Daylight Time NEW YORK & MONTREAL– Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, …
G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
– PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration– Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust myelopreservation benefits– G1 launching expanded access program (EAP) for …
HistoSonics Announces $40 Million Financing
Breakthrough medical platform offers vision of non-invasive procedures to eliminate diseased tissues and tumors MINNEAPOLIS, June 8, 2020 /PRNewswire/ — HistoSonics, developer of a non-invasive robotic platform and sonic beam therapy, announced today that it has closed $40 million in an …
UCB Acquires Engage Therapeutics: Staccato® Alprazolam – A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
– Staccato® Alprazolam could be a potential solution for 20-30% of epilepsy patients – Initial upfront payment of US$ 125 million and further potential milestone payments of up to US$ 145 million, total potential consideration of up to US$ 270 …